{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:48:56Z","timestamp":1761238136985},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Science and Technology of PR China","award":["2013ZX09402201"],"award-info":[{"award-number":["2013ZX09402201"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81473188"],"award-info":[{"award-number":["81473188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physiology & Behavior"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.physbeh.2014.10.007","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T02:23:04Z","timestamp":1413771784000},"page":"141-149","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor"],"prefix":"10.1016","volume":"138","author":[{"given":"Jian","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiying","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingguo","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.physbeh.2014.10.007_bb0005","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1602\/neurorx.2.4.590","article-title":"Innovative approaches for the development of antidepressant drugs: current and future strategies","volume":"2","author":"Schechter","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0010","doi-asserted-by":"crossref","first-page":"e1001547","DOI":"10.1371\/journal.pmed.1001547","article-title":"Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010","volume":"10","author":"Ferrari","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0015","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3949\/ccjm.73.4.351","article-title":"Side effects of antidepressants: an overview","volume":"73","author":"Khawam","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0025","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.1016\/j.euroneuro.2012.07.005","article-title":"Onset, time course and trajectories of improvement with antidepressants","volume":"22","author":"Lam","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0030","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2009.07.009","article-title":"Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic\/noradrenergic antidepressants during pregnancy: a review","volume":"1","author":"Tuccori","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0035","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1177\/0269881113492027","article-title":"A review of the adverse effects and safety of noradrenergic antidepressants","volume":"27","author":"Whiskey","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.npp.1301574","article-title":"Stress, depression, and neuroplasticity: a convergence of mechanisms","volume":"33","author":"Pittenger","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pneurobio.2010.06.003","article-title":"Depression and the role of genes involved in dopamine metabolism and signalling","volume":"92","author":"Opmeer","year":"2010","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archpsyc.64.3.327","article-title":"The role of dopamine in the pathophysiology of depression","volume":"64","author":"Dunlop","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0055","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.biopsych.2005.09.018","article-title":"The mesolimbic dopamine reward circuit in depression","volume":"59","author":"Nestler","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0060","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/da.20181","article-title":"The combination of duloxetine and bupropion for treatment-resistant major depressive disorder","volume":"23","author":"Papakostas","year":"2006","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejphar.2006.10.004","article-title":"Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050","volume":"555","author":"Shaw","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.biopsych.2005.06.027","article-title":"Use of bupropion in combination with serotonin reuptake inhibitors","volume":"59","author":"Zisook","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuroscience.2011.08.064","article-title":"Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties","volume":"196","author":"Tian","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0080","doi-asserted-by":"crossref","first-page":"657-565","DOI":"10.1124\/jpet.106.103382","article-title":"Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor","volume":"318","author":"Deecher","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0085","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.neuropharm.2013.02.024","article-title":"Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety","volume":"70","author":"Auclair","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0090","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.neubiorev.2005.03.008","article-title":"Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0095","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","article-title":"Depression: a new animal model sensitive to antidepressant treatments","volume":"266","author":"Porsolt","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/BF00181261","article-title":"The tail suspension test: ethical considerations","volume":"90","author":"Thierry","year":"1986","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0110","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0028-3908(83)90215-0","article-title":"The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist","volume":"22","author":"Colpaert","year":"1983","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbr.2011.12.017","article-title":"The antidepressant-like effect of fisetin involves the serotonergic and noradrenergic system","volume":"228","author":"Zhen","year":"2012","journal-title":"Behav Brain Res"},{"issue":"144","key":"10.1016\/j.physbeh.2014.10.007_bb0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jep.2012.10.013","article-title":"Antidepressant-like effects of the extract from Cimicifuga foetida L","volume":"18","author":"Ye","year":"2012","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF00433508","article-title":"Antagonism of hypothermia and behavioral response to apomorphine: a simple, rapid and discriminating test for screening antidepressants and neuroleptics","volume":"75","author":"Puech","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejphar.2010.06.043","article-title":"Antidepressant-like effect of scopoletin, a coumarin isolated from Polygala sabulosa (Polygalaceae) in mice: evidence for the involvement of monoaminergic systems","volume":"643","author":"Capra","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0135","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpsychires.2011.09.003","article-title":"Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Tran","year":"2012","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0145","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2174\/138945009789735156","article-title":"Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors","volume":"10","author":"Guiard","year":"2009","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0150","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1517\/13543784.2011.594039","article-title":"Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited","volume":"20","author":"Prins","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0155","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0160","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.pnpbp.2003.11.018","article-title":"Central monoamines and their role in major depression","volume":"28","author":"Elhwuegi","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0165","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejphar.2004.07.038","article-title":"The role of monoamines in the actions of established and \u201cnovel\u201d antidepressant agents: a critical review","volume":"500","author":"Millan","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","article-title":"Is there a role for 5-HT1A agonists in the treatment of depression?","volume":"53","author":"Blier","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0175","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.euroneuro.2010.02.013","article-title":"Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system","volume":"20","author":"Xu","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130050638","article-title":"Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity","volume":"138","author":"Redrobe","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0185","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.neuropharm.2005.06.002","article-title":"The antidepressant-like effect of Hypericum caprifoliatum Cham & Schlecht (Guttiferae) on forced swimming test results from an inhibition of neuronal monoamine uptake","volume":"49","author":"Viana","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0190","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.neubiorev.2005.03.006","article-title":"What should animal models of depression model?","volume":"29","author":"Frazer","year":"2005","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0195","first-page":"3","article-title":"The role of dopamine and norepinephrine in depression and antidepressant treatment","volume":"67","author":"Nutt","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jad.2004.12.010","article-title":"Dopaminergic mechanism of antidepressant action in depressed patients","volume":"86","author":"Willner","year":"2005","journal-title":"J Affect Disord"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0205","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.euroneuro.2005.12.002","article-title":"Dopaminergic-based pharmacotherapies for depression","volume":"16","author":"Papakostas","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s002130100836","article-title":"Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?","volume":"159","author":"Renard","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2014.10.007_bb0215","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejphar.2004.09.057","article-title":"Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test","volume":"504","author":"Yamada","year":"2004","journal-title":"Eur J Pharmacol"}],"container-title":["Physiology & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938414004727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938414004727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T07:27:06Z","timestamp":1538119626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031938414004727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":43,"alternative-id":["S0031938414004727"],"URL":"https:\/\/doi.org\/10.1016\/j.physbeh.2014.10.007","relation":{},"ISSN":["0031-9384"],"issn-type":[{"value":"0031-9384","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor","name":"articletitle","label":"Article Title"},{"value":"Physiology & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.physbeh.2014.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}